CS Genetics Appoints Bill Colston, PhD, as Chief Executive Officer
Experienced life-science entrepreneur to drive next generation of single cell biology
SAN DIEGO, Calif. and CAMBRIDGE, UK – Sept. 24, 2024 – CS Genetics, a privately held genomics technology company, today announced the appointment of Bill Colston, PhD, as Chief Executive Officer.
Bill joins CS Genetics with decades of experience as an inventor, entrepreneur, and executive in life sciences and biotechnology. He founded QuantaLife, where he pioneered the invention of droplet digital PCR (ddPCR), leading the company as CEO until its acquisition by Bio-Rad. He also founded Sestina Bio, a synthetic biology company, and HealthTell, a diagnostics firm. Earlier in his career, Bill directed the U.S. biologic and chemical defense R&D program at Lawrence Livermore National Laboratory and has served on numerous private and public boards. Bill holds a B.Sc. in Molecular Biology from the University of Texas at Austin and a Ph.D. in Biomedical Engineering from the University of California, Davis.
“I could not be more excited to welcome Bill to the team,” said Luke Edelman, founder and Chief Technology Officer at CS Genetics. “He’s a successful multi-time founder and CEO who knows the unique challenges of leading venture-stage companies, and the opportunities that come from successful execution. He has a rare mix of technical vision and aggressive commercial ambition that will serve in good stead as we build a large and enduring company through the years to come.”
CS Genetics has developed a next-generation instrument-free platform for single cell genomics that leverages a molecular process known as Kinetic Confinement to produce simple, scalable, and accessible workflows that plug seamlessly into standard lab infrastructure. This disruptive platform will expand the reach of single cell genomics to major underserved segments such as new-to-single cell customers and biopharma, and significantly broaden the use of single cell as a tool for scientific discovery, molecular diagnostics, and the development of new vaccines and therapeutics.
“I’ve been fortunate to be at the forefront of several breakthroughs in digital biology, and I believe now is the perfect time to introduce a new single cell technology. The market is evolving rapidly, and there’s a clear demand for tools that offer deep biological insights at unprecedented scale. CS Genetics has the right vision, talent, and technology to lead this next phase of innovation. I’m excited to join the team and help bring this platform to the forefront of the market,” said Bill Colston, Chief Executive Officer at CS Genetics.
About CS Genetics
CS Genetics is a privately held genomics-technology company based in Cambridge, UK and San Diego, California. The company has developed a radically new, instrument-free platform for single-cell genomics with disruptive simplicity, speed, and scalability that will launch a new era of NGS-based cellular analysis. The company’s technology leverages a molecular process known as Kinetic Confinement that is categorically different to other single cell technologies, and plugs seamlessly into standard, widespread lab infrastructure. The company holds a large global intellectual property estate covering its single cell platform and related reagent, workflow, manufacturing and application technologies. For more information, visit www.csgenetics.com.
Leave a Reply